Lipid metabolism dysregulation in diabetic retinopathy
1Department of Physiology, Michigan State University, East Lansing, MI, USA.
Abstract:
Lipid metabolic abnormalities have emerged as potential risk factors for the development and progression of diabetic complications, including diabetic retinopathy (DR). This review article provides an overview of the results of clinical trials evaluating the potential benefits of lipid-lowering drugs, such as fibrates, omega-3 fatty acids, and statins, for the prevention and treatment of DR. Although several clinical trials demonstrated that treatment with fibrates leads to improvement of DR, there is a dissociation between the protective effects of fibrates in the retina, and the intended blood lipid classes, including plasma triglycerides, total cholesterol, or HDL:LDL cholesterol ratio. Guided by these findings, plasma lipid and lipoprotein-independent mechanisms are addressed based on clinical, cell culture, and animal model studies. Potential retinal-specific effects of fatty acid oxidation products, cholesterol, and ceramide, as well as lipid-independent effects of PPAR alpha activation, are summarized based on the current literature. Overall, this review highlights promising potential of lipid-based treatment strategies further enhanced by the new knowledge of intraretinal lipids and lipoproteins in DR.
Insights
Lipid-lowering drugs show promise for diabetic retinopathy (DR). Fibrates improve DR, but mechanisms extend beyond blood lipids, involving intraretinal lipid pathways and PPAR alpha activation.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Lipid metabolic abnormalities are risk factors for diabetic complications, including diabetic retinopathy (DR).
- Understanding the role of lipids in DR pathogenesis is crucial for developing effective treatments.
Purpose of the Study:
- To review clinical trial data on lipid-lowering drugs for DR prevention and treatment.
- To explore lipid-independent mechanisms of DR progression and potential therapeutic targets.
Main Methods:
- Review of clinical trials evaluating fibrates, omega-3 fatty acids, and statins in DR.
- Analysis of cell culture and animal models to investigate intraretinal lipid metabolism.
- Examination of PPAR alpha activation pathways.
Main Results:
- Fibrates demonstrate protective effects in DR, yet dissociation exists between blood lipid changes and retinal benefits.
- Evidence suggests intraretinal lipid species (fatty acid oxidation products, cholesterol, ceramide) play a role in DR.
- PPAR alpha activation shows potential therapeutic benefits independent of systemic lipid modification.
Conclusions:
- Lipid-based treatments offer potential for DR management.
- Further research into intraretinal lipid pathways and PPAR alpha activation is warranted for novel therapeutic strategies.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Type 2 and Gestational
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...